Clinical trials: LTBI
Latent Tuberculosis
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care…
- Trial name
- ASTERoiD (NCT03474029)
- Testing
- Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks
- Where
- 21 sites in United States, Australia and 6 more
- Volunteers
- 3,400 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis, Pulmonary, Mycobacterium Tuberculosis Infection
Clinic-based Versus Hotspot-focused Active TB Case Finding
This five-year study will evaluate two strategies for conducting tuberculosis (TB) active case finding (ACF) and linkage to TB treatment or TB preventive therapy (TPT) in peri-urban Uganda.
- Trial name
- CHASE-TB (NCT05285202)
- Testing
- Active TB case finding with linkage to preventive therapy (ACF/TPT)
- Where
- Uganda
- Volunteers
- 146,539 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Renal Transplant
Latent Tuberculosis Infection in Renal Transplant Recipients
The aim of this study is to estimate the usefulness of a T cell-based assay (i.e. T-SPOT.TB assay) for diagnosis of latent tuberculosis infection (LTBI) in renal transplant recipients.
- Trial name
- NCT00682045
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Asan Medical Center
Tuberculosis
Early Risk Assessment in Household Contacts (≥10 Years) of TB Patients by New Diagnostic Tests in 3 African Countries
The ERASE - TB study will be conducted in order to fill a critical unmet need for tuberculosis control. Persons who are in contact with an infectious TB case may become infected themselves.
- Trial name
- ERASE-TB (NCT04781257)
- Testing
- New test candidates
- Where
- 3 sites in Mozambique, Tanzania and 1 more
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Michael Hoelscher
Tuberculosis, Mycobacterium Tuberculosis
Diagnosis of Tuberculosis in Swiss Children
1. The primary objective is to improve the sensitivity of novel immunodiagnostic tests for detection of TB disease in children. 2.
- Trial name
- CITRUS (NCT03044509)
- Testing
- Secreted cytokine assay, Intracellular cytokine assay
- Where
- 8 sites in Switzerland
- Volunteers
- 190 people
- Sponsor
- University Children's Hospital Basel
Advanced Cancer
Latent Tuberculosis Infection in Cancer Patients
Primary Objective: 1. To evaluate the performance of the new T-SPOT.TB test and the conventional TST for screening of Latent Tuberculosis infections in patients with cancer and those undergoing Hematopoietic Stem Cell Transplant.
- Trial name
- NCT00507754
- Testing
- T-SPOT TB test
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Tuberculosis
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
Open-label, multi-center, Phase III clinical trial to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month…
- Trial name
- PREVENT TB (NCT00023452)
- Testing
- RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 8,053 people
- Sponsor
- Centers for Disease Control and Prevention
TB - Tuberculosis
Start4All - Start Taking Action for TB Diagnosis (DARE-TB)
DARE-TB has been designed to address critical evidence gaps on the diagnostic performance and operational value of near point-of-care (NPOC) nucleic acid amplification tests (NAATs) within community-based case finding (CBCF)…
- Trial name
- S4A-DARE-TB (NCT07420881)
- Testing
- Near point of care (NPOC) NAATs, Low-complexity nucleic acid amplification tests (LC-NAATs), LC-NAAT using pooled testing
- Volunteers
- 60,000 people
- Sponsor
- Liverpool School of Tropical Medicine
Close Contacts of Active Tuberculosis
Efficacy of Nyaditum Resae(R) Against Active TB in Georgia
The use of a supplement food like "Nyaditum resae" is a reliable opportunity to stop the progression towards active TB through the most updated knowledge of this disease:the induction of tolerance.
- Trial name
- NCT02897180
- Testing
- Nyaditum resae(R)
- Where
- Georgia
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- Fundació Institut Germans Trias i Pujol
Tuberculosis
Spatial Epidemiology of Tuberculosis (TB) Infection
Data will be extracted from the NTUH medical records database, geocoded according to the street address so that the case number, incidence, etc could be mapped.
- Trial name
- NCT00780546
- Where
- Taiwan
- Volunteers
- 1,000 people
- Sponsor
- National Taiwan University Hospital
Tuberculosis, Tubercular Meningitis
Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis
Tubercular meningitis occurs in around 10% of those with extrapulmonary tuberculosis and is a major cause of mortality and morbidity.
- Conditions
- Tuberculosis, Tubercular Meningitis, Arachnoiditis; Tuberculous (Etiology)
- Trial name
- NCT04620772
- Testing
- Cyclophosphamide injection
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences
Latent Tuberculosis Infection
Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)
Tuberculosis (TB) is spread by airborne transmission from adults with active contiguous TB to children, especially those living in the same household.
- Trial name
- NCT00170209
- Testing
- Isoniazid, Rifampin
- Where
- 9 sites in Australia, Benin and 5 more
- Volunteers
- 844 people
- Sponsor
- McGill University
Latent Tuberculosis Infection, Tuberculosis
Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
This is a prospective cohort study of persons tested for latent tuberculosis infection at either high risk for exposure to Mycobacterium tuberculosis or high risk for progression to tuberculosis disease.
- Trial name
- NCT01622140
- Where
- 10 sites in United States
- Volunteers
- 21,334 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis Infection
Intensifying Multi-Drug Resistant Tuberculosis Contact Tracing by Social Network Analysis
Tuberculosis burden in Vietnam increasing with contribution from low detection rates and increased drug resistance. There is a need to identify MDR-TB (MultiDrug Resistant Tuberculosis) among both notified TB cases and their…
- Trial name
- SNAP (NCT02175849)
- Where
- Vietnam
- Volunteers
- 596 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Active Tuberculosis, Latent Tuberculosis Infection
Performance Evaluation of the VIDAS TB-IGRA Assay.
This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection.
- Conditions
- Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
- Trial name
- NCT04048018
- Testing
- Blood draw and IGRA test
- Where
- 24 sites in United States, Brazil and 7 more
- Volunteers
- 2,401 people, healthy volunteers welcome
- Sponsor
- BioMérieux
Tuberculosis, HIV Coinfection
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
Tuberculosis (TB) is the world's leading infectious cause of mortality and responsible for 1/3 of deaths in people living with human immunodeficiency virus (PLHIV).
- Conditions
- Tuberculosis, HIV Coinfection, Tuberculosis Infection
- Trial name
- TB_GAPS (NCT05342064)
- Testing
- patient-centered TB preventive therapy, TB preventive therapy adherence support
- Where
- 5 sites in Eswatini, Lesotho and 3 more
- Volunteers
- 5,733 people
- Sponsor
- Baylor College of Medicine
Tuberculosis
Taima TB: 3HP Study
This phase IV clinical study trial will be conducted among persons who require treatment for LTBI treatment in Iqaluit, Nunavut and Ottawa, Ontario.
- Trial name
- NCT02689089
- Testing
- 3HP
- Where
- Canada
- Volunteers
- 182 people
- Sponsor
- Ottawa Hospital Research Institute
Latent Tuberculosis Infection
Clinical Trial of Mica
This study used a randomized, open, blank control design. A total of 6800 patients over 15 years old with latent mycobacterium tuberculosis infection who met the inclusion criteria but did not meet the exclusion criteria were…
- Trial name
- NCT05680415
- Testing
- Mycobacterium Vaccae for Injection
- Where
- 2 sites in China
- Volunteers
- 6,800 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Tuberculosis
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB).
- Trial name
- NCT07124559
- Testing
- Rifapentine, Isoniazid, Dolutegravir
- Where
- 11 sites in Botswana, Haiti and 4 more
- Volunteers
- 144 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Children LTBI
A Multicentre, Cohort Study of Screening and Preventive Intervention for Latent Tuberculosis Infection in Children
The management of latent Mycobacterium tuberculosis infection is a new priority action for the WHO End Tuberculosis (TB) Strategy.
- Trial name
- NCT04156568
- Testing
- INH、RFT
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Children's Hospital